Free Trial!
Today’s Best Stocks To Trade! Click Here
Visit http://www.otcpicks.com to register for our Daily Market Mover's Digest Newsletter and Email Stock Watch Alerts.
BIOSOLAR INCORPORATED (OTC: BSRC | Quote | Chart | News | PowerRating) "Up 5.56% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/BSRC.php
Company Profile: http://www.otcpicks.com/biosolar/biosolar-2.htm
BioSolar, Inc. engages in the research and development of bioplastic materials from renewable plant sources for use in photovoltaic solar cells. The company develops bio-based plastics components that meet the thermal and durability requirements of solar cell manufacturing processes for conventional crystalline cell designs, as well as thin film photovoltage devices in an effort to capitalize on cost advantages to current petroleum based solar cell components. Its bioplastic materials can be also used directly in conventional manufacturing systems, such as injection molding and thin-film roll-to-roll, to create superstrate layer, substrate layer, and backsheet, as well as module and panel components. The company was founded in April 2006. It was formerly known as BioSolar Labs, Inc. and changed its name to BioSolar, Inc. in June 2006. BioSolar, Inc. is headquartered in Santa Clarita, California.
BSRC News:
June 11 - BioSolar Highlighted Nationally in Media Reports Focused on Growth of Solar Market and Company's Competitive Advantage
Company's BioBacksheet Causing Industry-Wide Interest in Shift to Petroleum-Free Components to Ensure that Entire Solar Industry Becomes Financially Sustainable
BioSolar, Inc. (OTCBB: BSRC), developer of a breakthrough technology to produce bio-based materials from renewable plant sources that reduce the cost of photovoltaic solar cells, has been cited in recent news media reports exploring the increasing demand for bio-based solar cell components, which will help the entire industry make photovoltaic solar cells more financially viable by substantially lowering the cost of the cells through the use of petroleum-free materials.
In this week's CLEANTECH column in energy trade publication California Energy Circuit, (CLEANTECH: Making Solar Power Fossil Free, June 6 2008 issue), energy correspondent William J. Kelly discusses the concept of life-cycle testing - utilizing the entire life-cycle of a product and its components to determine its total carbon footprint - noting that solar cells generate 0.04 kilograms of carbon dioxide per kilowatt of electricity generated.1 The article goes on to note that clean energy researchers see that level declining dramatically due to improvements in the materials used to make the solar cells.
"This article recognizes that BioSolar's BioBacksheet is quickly becoming a driving force in a shift to replace plastic petroleum-based solar cell components with environmentally-friendlier fossil-free ones derived from plant-based products," said Dr. David Lee, CEO of BioSolar. "This industry-wide trend is expected to continue accelerating as the cost benefits of bio-based products continue to far outperform petroleum-based products. Plus, by making solar cells fossil-free, we are also making the solar cell - and the entire solar industry - more financially sustainable. Products like the BioBacksheet, among other new products from BioSolar, are helping the industry attain its long sought goal of weaning itself from governmental subsidies and achieving economic viability."
BioSolar was also the subject of a piece in GreenTech Pastures, veteran newsman Harry Fuller's column at ZDnet.com (http://blogs.zdnet.com/green/?p=1083). Noting that BioSolar's "BioBacksheet" is made entirely of plant-based materials, Mr. Fuller's article states that BioSolar has found a "way to really green solar: turning green plants into photovoltaics."
The article also highlights another compelling business point: while other bio-based plastics are made from corn-starch or potato-starch derivatives, which are currently experiencing a surge in price, all of the plant-based materials used by BioSolar's products are made from plants that are non-food based. This bodes well for the company's pricing and market penetration strategy because BioSolar is more insulated from the negative effects of the recent run-up in food commodity pricing.
"This article is further evidence that we are succeeding in our mission to lead the industry both in terms of appealing to our customer base as well as industry influencers and that the products in our development pipeline are poised to experience the same rapid market acceptance in the multi-billion dollar photovoltaic market," said Lee.
LANTIS LASER INCORPORATED (OTC: LLSR | Quote | Chart | News | PowerRating) "Up 4.35% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/LLSR.php
Company Profile: http://www.otcpicks.com/lantis-laser/lantis-laser-2.htm Lantis Laser was formed to commercialize the application of novel technologies in the dental industry. The criteria for selected products include competitive edge, exclusivity and large market potential. Lantis is currently in Phase 2 development, moving through beta systems, product development and application for FDA clearance and plans to launch the OCT Dental Imaging System in the first quarter of 2009. Lantis has exclusive rights to the application of OCT technology in the field of dentistry under its license Agreements with Lawrence Livermore National Laboratory (exclusive); LightLab Imaging (non-exclusive) and AXSUN (exclusive). To find out more about Lantis Laser, visit www.lantislaser.com.
LLSR News:
June 10 - Lantis Laser Commences Phase 3 Development of it's OCT Light-Based Dental Imaging System
Eclipse Product Development Selected for Design, Interface and Documentation Phase
Lantis Laser Inc. (OTC: LLSR | Quote | Chart | News | PowerRating) (www.lantislaser.com) announced that it has commenced Phase 3 of the development cycle of its proprietary, highly advanced Optical Coherence Tomography (OCT) Dental Imaging System. The OCT System is a diagnostic light-based, chairside, system that images in real-time at a resolution of to 10 times x-ray and without any harmful radiation. It is expected to have a major impact on early diagnostics and the advancement of minimally invasive treatment once it is deployed in dental offices.
"Phase 3 development embodies a number of significant events in the evolution of OCT for dentistry," said Stan Baron, president and CEO of Lantis. "The components of the OCT System that needed to be upgraded to meet the requirements of the fast scanning speed enabled by AXSUN Technologies swept source laser, are being readied for integration into the OCT Beta Systems. We expect to deploy the Beta Systems for clinical use in the July/August timeframe."
Phase 3 of the product development cycle also requires that the OCT System's mobile cart will be designed, that the user interface be refined and that documentation in preparation for the FDA filing be prepared. After an extensive review of product design companies, Lantis is pleased to announce that it has selected Eclipse Product Development to undertake this demanding task.
Vice President of Research and Development at Lantis, Doug Hamilton, commented, "OCT is not a modality that many companies have had experience with, so we looked for a company that had a solid industrial design core and the network to bring in the best available resources for each discipline that is deployed in the OCT System. Eclipse provides us with this development model and the flexibility we need to complete this Phase in an efficient and timely manner."
"All the components leading to up to FDA submission, manufacturing and marketing are now being put into place," said Baron. "We will be making regular announcements as we progress to keep the investment and dental community abreast of developments".
ABOUT ECLIPSE PRODUCT DEVELOPMENT
Eclipse, located in Amesbury, MA has over 13 years of experience helping clients commercialize medical, laboratory and dental category technologies. The company is medically oriented and has designed numerous products including complex diagnostic and therapeutic medical and dental equipment and devices. Their development process meets FDA and ISO requirements for design control documentation and verification. Eclipse has developed a strategic business model to include several experienced molding and manufacturing vendor relationships.
ACCENTIA BIOPHARMACEUTICALS (NASD: ABPI | Quote | Chart | News | PowerRating) "Up 33.94% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/BPAX.php
Accentia Biopharmaceuticals, Inc., a biopharmaceutical company, together with its subsidiaries, develops and commercializes drug candidates that are in late-stage clinical development based on active pharmaceutical ingredients in the therapeutic areas of respiratory disease and oncology. It operates in two segments: Biopharmaceutical Products and Services, and Specialty Pharmaceuticals. The Biopharmaceutical Products and Services segment develops late-stage biopharmaceutical products. Its products, which are under Phase III clinical trials, include SinuNase for the treatment of chronic rhinosinusitis; BiovaxID, a patient-specific anti-cancer vaccine focusing on the treatment of follicular non-Hodgkins lymphoma; and Revimmune for the treatment of multiple sclerosis, an autoimmune disease that affects the central nervous system, and various autoimmune diseases, including systemic lupus, myasthenia gravis, and aplastic anemia. This segment also provides various consulting services relating to biopharmaceutical product development; and engages in the production of custom biologic products and cell culture instruments and systems for biopharmaceutical and biotechnology companies, medical schools, universities, hospitals, and research institutions. The Specialty Pharmaceuticals segment markets and sells pharmaceutical products that are developed primarily by third-party development partners. Its products comprise Respi-TANN, a prescription antitussive decongestant for temporary relief of cough and nasal congestion; SinuTest, a test used in connection with the diagnosis of chronic sinusitis; and Zinotic, a treatment of superficial infections of the external ear. This segment's products under development include AllerNase, a formulated suspension of an intranasal topical steroid indicated for the treatment of allergic and non-allergic rhinitis; and Emezine, a product for control of nausea and vomiting. The company was founded in 2002 and is headquartered in Tampa, Florida.
ABPI News:
June 11 - Biovest Reports Blinded Results for Phase 3 Study Evaluating Anti-Cancer Vaccine, BiovaxID(R), which Shows 100% Difference in Disease-Free Survival at 36 Months in the Comparative Arms
Final Unblinded Results Are Expected to Confirm Efficacy Of BiovaxID for the Treatment of Non-Hodgkin's Lymphoma
Biovest International, Inc. (OTCBB: BVTI), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (NASD: ABPI), reported what the Company believes to be highly encouraging blinded results from its randomized controlled pivotal Phase 3 Fast-Tracked clinical trial of BiovaxID (anti-idiotype vaccine) for the treatment of indolent follicular non-Hodgkin's lymphoma (NHL), an often fatal blood cancer.
The Company reported blinded disease-free survival data for those patients that have completed 36 months of follow-up subsequent to randomization in both the treatment and control arms, with one arm demonstrating 100% improvement in disease-free survival over the other arm. Disease-free survival (how long patients remain in cancer-free remission) is the primary endpoint of the study.
According to Steven Arikian, M.D., Chairman and CEO of Biovest International, "In the accompanying graph, one curve shows those patients at 36 months in the BiovaxID arm and the other curve shows those patients at 36 months in the control arm who received a non-specific immunostimulant (KLH/GM-CSF).
"Although these results are blinded, this data shows two distinct populations in the study, with unequivocal evidence of a difference in disease-free survival among the two arms. This is in direct contrast to previous anti-NHL vaccine failures which showed little difference between the treatment arm and the control arm. Based on the similar pattern to our Phase 2 data, we have a high degree of confidence that the cohort demonstrating superior disease-free survival represents the BiovaxID arm," stated Dr. Arikian.
Dr. Angelos Stergiou, Biovest's Vice President, Product Development, added, "We know that in our Phase 2 trial, the control arm showed a median disease-free survival of approximately 20 months, which is consistent with the inferior arm in our blinded Phase 3 results, and supports our strong belief that the group demonstrating clinical benefit is the BiovaxID arm."
ABOUT BIOVAXID
BiovaxID is a personalized, patient-specific therapeutic vaccine designed to stimulate the patient's own immune system to recognize and destroy cancerous B-cells that may remain in the body or may arise after the patient has been treated with chemotherapy. Unlike many other approaches to treating non-Hodgkin's lymphoma, BiovaxID is designed to kill only cancerous B-cells, with the initial indication of follicular non-Hodgkin's lymphoma. Additionally, we anticipate that BiovaxID could potentially be used to treat other types of B-cell cancers, such as Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia and Multiple Myeloma.
ABOUT BIOVEST INTERNATIONAL INC.
Biovest International, Inc. is a pioneer in the development of advanced individualized immunotherapies for life-threatening cancers of the blood system. Biovest is a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc., with its remaining shares publicly traded. Biovest has a foundation in the manufacture of biologics for research and clinical trials. In addition, Biovest develops, manufactures and markets patented cell culture systems, including the innovative AutovaxID, which is being marketed as an automated vaccine manufacturing instrument and for production of cell-based materials and therapeutics. Biovest is currently conducting a pivotal Phase 3 clinical trial for BiovaxID , which is a patient-specific anti-cancer vaccine focusing on the treatment of follicular non-Hodgkin's lymphoma. BiovaxID has been granted Fast Track status by the FDA and Orphan Drug status by the EMEA.
BIOVEST INTERNATIONAL INCORPORATED (OTCBB: BVTI | Quote | Chart | News | PowerRating) "Up 24.39% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/BVTI.php Biovest International, Inc., a biotechnology company, develops therapeutic anti-cancer vaccine for the treatment of low-grade Follicular Lymphoma in the United States. It develops BiovaxID, a Phase III clinical trial product, which is an injectable patient-specific vaccine to treat the follicular form of non-Hodgkin's lymphoma. The company develops, manufactures, and markets cell culture systems, equipment, and consumable parts to pharmaceutical, diagnostic, and biotechnology companies, as well as to research institutions worldwide. Biovest International also produces mammalian and insect cells, monoclonal antibodies, recombinant and secreted proteins, and other cell culture products using hollow fiber perfusion. It is also developing an automated cell culture instrument, AutovaxID that enables production of personalized cell-based treatments. In addition, the company sells hollow fiber bioreactors, cultureware, tubing sets, and other disposable products and supplies. Further, Biovest International engages in the production and contract manufacture of biologic drugs and cell production for research institutions. The company has a cooperative research and development agreement with the National Cancer Institute for the development and commercialization of patient-specific vaccines for the treatment of non-Hodgkin's low-grade follicular lymphoma. Its customers include biopharmaceutical and biotech companies, medical schools, universities, research facilities, hospitals, and public and private laboratories. The company was incorporated in 1981 as Endotronics, Inc. and changed its name to Cellex Biosciences, Inc. in 1993. Further, it changed its name to Biovest International, Inc. in 2001. The company is based in Worcester, Massachusetts. Biovest International, Inc. is a subsidiary of Accentia Biopharmaceuticals, Inc.
BVTI News:
June 11 - Biovest Reports Blinded Results for Phase 3 Study Evaluating Anti-Cancer Vaccine, BiovaxID(R), which Shows 100% Difference in Disease-Free Survival at 36 Months in the Comparative Arms
Final Unblinded Results Are Expected to Confirm Efficacy Of BiovaxID for the Treatment of Non-Hodgkin's Lymphoma
Biovest International, Inc. (OTCBB: BVTI), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (NASD: ABPI), reported what the Company believes to be highly encouraging blinded results from its randomized controlled pivotal Phase 3 Fast-Tracked clinical trial of BiovaxID (anti-idiotype vaccine) for the treatment of indolent follicular non-Hodgkin's lymphoma (NHL), an often fatal blood cancer.
The Company reported blinded disease-free survival data for those patients that have completed 36 months of follow-up subsequent to randomization in both the treatment and control arms, with one arm demonstrating 100% improvement in disease-free survival over the other arm. Disease-free survival (how long patients remain in cancer-free remission) is the primary endpoint of the study.
According to Steven Arikian, M.D., Chairman and CEO of Biovest International, "In the accompanying graph, one curve shows those patients at 36 months in the BiovaxID arm and the other curve shows those patients at 36 months in the control arm who received a non-specific immunostimulant (KLH/GM-CSF).
"Although these results are blinded, this data shows two distinct populations in the study, with unequivocal evidence of a difference in disease-free survival among the two arms. This is in direct contrast to previous anti-NHL vaccine failures which showed little difference between the treatment arm and the control arm. Based on the similar pattern to our Phase 2 data, we have a high degree of confidence that the cohort demonstrating superior disease-free survival represents the BiovaxID arm," stated Dr. Arikian.
Dr. Angelos Stergiou, Biovest's Vice President, Product Development, added, "We know that in our Phase 2 trial, the control arm showed a median disease-free survival of approximately 20 months, which is consistent with the inferior arm in our blinded Phase 3 results, and supports our strong belief that the group demonstrating clinical benefit is the BiovaxID arm."
ABOUT BIOVAXID
BiovaxID is a personalized, patient-specific therapeutic vaccine designed to stimulate the patient's own immune system to recognize and destroy cancerous B-cells that may remain in the body or may arise after the patient has been treated with chemotherapy. Unlike many other approaches to treating non-Hodgkin's lymphoma, BiovaxID is designed to kill only cancerous B-cells, with the initial indication of follicular non-Hodgkin's lymphoma. Additionally, we anticipate that BiovaxID could potentially be used to treat other types of B-cell cancers, such as Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia and Multiple Myeloma.
ENZYME ENVIRONMENTAL SOLUTIONS (OTC: EESO | Quote | Chart | News | PowerRating) "Up 12.50% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/EESO.php
Enzyme Environmental Solutions is a U.S.-based manufacturer of industrial and agricultural enzyme products. All manufacturing, testing, and formulating are conducted in its manufacturing plant, located in Fort Wayne, Indiana. EESO strives to become a leader in ecological friendly or "green products" targeting the industrial and agricultural markets. It is the company's goal to have the best performing products on the market in each industry. Developing a growing and satisfied customer base is its number one marketing strategy.
EESO News:
June 11 - Enzyme Environmental Solutions Finalizes Agreement With Canada's Largest Food Service Brokerage
Enzyme Environmental Solutions Inc. (OTC: EESO | Quote | Chart | News | PowerRating) CEO S. Jared Hochstedler announced that the company has finalized the agreement to supply International Pacific Sales, LTD with sustainable cleaning products.
Hochstedler commented, "I am extremely pleased to announce that EESO has now contracted with International Pacific Sales, LTD, www.internationalpacificsales.com, to supply our enzyme based cleaning products across all of western Canada."
Hochstedler continued, "This is another huge step for the company. I have been negotiating with International Pacific Sales, LTD for several weeks and am proud to be associated with such a prestigious company. International Pacific Sales, LTD is well known for its integrity, stability and high standards of professionalism. Mike Discroll, President of IPS, was the first Food Service broker to receive the 'We Care Hall of Fame Award.'"
The Company projects revenues between $1 and $4 million over the next 12 months with initial revenues beginning in July and in full swing by the end of the third quarter 2008.
"This continues to be an exciting time for our company. I am getting calls from in and outside the U.S. inquiring about our products. There has been much effort from everyone absorbing the efforts of our sales team that took place in the preceding months. The build out of the office and warehouse is just about completed and we have scheduled our Grand Opening for June 27, 2008. However all shareholders should feel free to stop in anytime," stated Hochstedler.
"I will be providing some updated revenue projections for 2008 and 2009 in the coming days; however I am pleased with the progress we have made thus far. On line sales have continued to outpace my expectations and I am pleased to relay we have received very positive feedback concerning the effectiveness of our products," concluded Hochstedler.
CYBERHAND TECHNOLOGIES INTERNATIONAL (OTC: CYHA | Quote | Chart | News | PowerRating) "Up 18.42% in morning trading"
Detailed Quote: http://www.otcpicks.com/quotes/CYHA.php
CyberHand Technologies International, Inc., through its Canadian operating subsidiary, design, market, sell, distribute and provide service for new consumer electronic technologies. These products use innovative ergonomic designs and technologies that are superior to other products in the market. The initial product offering includes: Computer Game Controllers that are 40% more responsive then the competitor's products; Wireless Keyboards for Personal Digital Assistants (PDAs"); Ergonomic Computer Mouse Product line that eliminates computer related Respective Stress Injuries; and Related Software Upgrades and other peripherals such as Keyboards, Cameras and Scanners. The products are patent protected in both Canada and the United States.
CYHA News:
June 10 - Black Widow Prerelease for Gamers Who Want an Edge
Cyberhand Technologies International Inc. (OTC: CYHA), a design, marketing and distribution company providing new consumer electronic technologies using innovative ergonomic designs, today announced its subsidiary, Cyberhand Robotics, has moved to the field testing of its first controller on the gaming and engineering design marketplace. The first product is called the "Black Widow" and will be accompanied by a Pro version almost immediately for more serious gamers. It is far faster than any gaming controller offered at any price, cannot cause any of the five carpel tunnels of any of the RMS problems normally associated with fast accurate use of pointing devices and allows substantially longer game play without fatigue. This is the first in a line of patented advanced controllers that will be offered by the company.
"Cyberhand will be releasing 500 of its Black Window controllers to qualified testers who will receive a fifty percent (50%) discount to release retail for their participation and control testing in advance of its fall release. They must sign a strict non-disclosure agreement and provide the company feedback and suggestions. All interested testers will be able to sign up on the company website. The Controller allows you to fight harder, move faster, dodge at lightning speed, play for hours without fatigue or pain and crush your opponents. You will be able to design faster, connect pieces easier and relax while you do complex on-screen tasks like you have never experienced them before. At Cyberhand, we invite you to come and test the Black Window and help change the world of gaming pointing devices forever!" said Patrick Burke, Inventor at Cyberhand Technologies International Inc.
ABOUT CYBERHAND ROBOTICS
Cyberhand Robotics Corporation, a subsidiary of Cyberhand Technologies International Inc., is a new Company that consists of all the technology and intellectual property related to the development of an Ergonomic Computer Mouse and a line of Computer Game Controllers. A unique feature of the Ergonomic Computer Mouse is its ability to eliminate computer related respective stress injuries such as carpal tunnel syndrome. The Computer Game Controllers integrate hand movement which, in turn, permit a variety of control functions to be performed by a single left or right handed operation resulting in a significant increase in response times over competing products making it the fastest, most intelligent, and most comfortable first person shooter controller on the market. In the gaming world, where split second timing and agility determine the winners and losers, the Company's game controllers place users at the top of any game as they are 40% more responsive than competitor products. The markets for the Company's products are huge, consisting of the Computer Peripheral market with over 600,000,000 users worldwide and the Computer Gaming Peripherals market estimated at $6 billion dollars in the U.S. alone, with this market growing at the rate of 34% per year.
OTCPicks.com is located at 3533 Twin Lakes Drive, Prosper, TX 75078, Telephone: (972) 546-3740, Email: Publisher@OTCPicks.com. OTCPicks.com is not a registered investment adviser or broker/dealer. OTCPicks.com makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. You are receiving this email because you have registered on OTCPicks.com or one of our affiliate companies.
ABOUT OTCPICKS.COM
OTCPicks.com is an Internet destination for investors seeking information on smallcap and microcap companies. The web site features companies in Profile Campaigns, Executive Interviews and Profile Research Reports authored by our financial writers. We publish a daily Newsletter to subscribers, and we publish our Daily Market Movers Digest which is sent out on the M2 Presswire several times daily highlighting hot OTC and OTCBB stocks. To feature a company on our web site or in our daily Newsletter or Market Mover's Digest, please contact our publisher, Brian Dean at 972-546-3740, or via email at publisher@otcpicks.com.
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. This disclaimer is to be read and fully understood before using our site, or joining our email list. PLEASE NOTE: The OTCPicks.com employees are NOT Registered as an Investment Advisor in any jurisdiction whatsoever.
Release of Liability:Through use of this website viewing or using you agree to hold OTCPicks.com, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a representation by the publisher nor a solicitation of the purchase or sale of any securities. OTCPicks is receiving nine thousand dollars by a third party (BlueWave Advisors) for BSRC advertising and promotion services. OTCPicks.com has been compensated two hundred thousand restricted 144 shares from a third party for LLSR advertising and promotional services. For a complete list of disclosures go to http://www.otcpicks.com/disclosure_details.php. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. The owner, publisher, editor and their associates are not responsible for errors and omissions. They may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. OTCPicks.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and OTCPicks.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. OTCPicks.com and its affiliates are not registered investment advisors or a broker dealers. OTCPicks.com has been advised that the investments in companies profiled are considered to be high risk and use of the information provided is at the investor's sole risk. OTCPicks.com also advises that the purchase of such high risk securities may result in the loss of some or all of the investment. Investors should not rely solely on the information presented. Rather, investors should use the information provided by the profiled companies as a starting point for doing additional independent research on the profiled companies in order to allow the investor to form his or her own opinion regarding investing in the profiled companies. Factual statements made by the profiled companies are made as of the date stated and are subject to change without notice. Investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. OTCPicks.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through OTCPicks.com. OTCPicks.com owners may or may not hold positions in the companies that are profiled.
The information contained herein contains forward-looking information within the meaning of Section 27A of the Securities Act of 1993 and Section 21E of the Securities Exchange Act of 1934 including statements regarding expected continual growth of the company and the value of its securities. In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 it is hereby noted that statements contained herein that look forward in time which include everything other than historical information, involve risk and uncertainties that may affect the company's actual results of operation. Factors that could cause actual results to differ include the size and growth of the market for the company's products, the company's ability to fund its capital requirements in the near term and in the long term, pricing pressures, unforeseen and/or unexpected circumstances in happenings, pricing pressures, etc. Investing in securities is speculative and carries risk. Past performance does not guarantee future results.
Third Party Web Sites and Information:
OTCPicks.com and newsletter may provide hyperlinks to third party websites or access to third party content. OTCPicks.com does not control, endorse, or guarantee content found in such sites. You agree that OTCPicks.com is not responsible for any content, associated links, resources, or services associated with a third party site. You further agree that OTCPicks.com shall not be liable for any loss or damage of any sort associated with your use of third party content. Links and access to these sites are provided for your convenience only.
CONTACT: Brian Dean, Publisher, OTCPicks.com Tel: +1 972 546 3740 e-mail: publisher@otcpicks.com
M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
